Angelini Pharma

Angelini Pharma, founded in 1919, is an international pharmaceutical entity operating as a division of Angelini Industries. The company specializes in the research, development, manufacturing, and commercialization of therapeutic solutions, with a primary focus on brain health, including mental health and epilepsy, alongside consumer healthcare products. With over a century of operational history, the firm maintains a robust presence in more than 70 countries, leveraging its expertise to address complex medical needs through innovation.

The organization currently employs 1,000-5,000 employees who support its global operations across two primary locations. Angelini Pharma integrates advanced pharmaceutical manufacturing with a commitment to patient quality of life, delivering high-standard therapeutic interventions. Meet Angelini Pharma's team to understand the organizational structure and the specialized talent driving their R&D and commercialization efforts. The company’s technical portfolio includes generic pharmaceuticals, disinfection products, and specialized drugs designed for pain management and neurological conditions.

As a key player in the healthcare sector, Angelini Pharma maintains a strategic focus on B2B and B2C markets, ensuring consistent delivery of medical solutions. The company’s revenue is approximately $911.4M, reflecting its significant market footprint and operational scale. By prioritizing innovation in the pharmaceutical sector, the firm continues to expand its therapeutic reach, addressing daily health requirements through a diverse product pipeline. Their commitment to scientific advancement and patient-centric care remains central to their long-term growth strategy within the competitive global pharmaceutical landscape.